Lyra Therapeutics, Inc.
General ticker "LYRA" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $236.0M (TTM average)
Lyra Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -5.3%.
Estimated limits based on current volatility of 7.3%: low 3.83$, high 4.44$
Factors to consider:
- Total employees count: 30 (-65.9%) as of 2024
- Top business risk factors: Going concern, Product development delays, Regulatory and compliance, Manufacturing risks, Market competition
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.05$, 12.47$]
- 2025-12-31 to 2026-12-31 estimated range: [2.96$, 11.07$]
Financial Metrics affecting the LYRA estimates:
- Negative: with PPE of -9.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -11.62 <= 0.33
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 13.33 > -0.66
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 17.48 <= 18.93
Short-term LYRA quotes
Long-term LYRA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.36MM | $1.56MM | $1.53MM |
| Operating Expenses | $57.67MM | $68.68MM | $97.88MM |
| Operating Income | $-56.31MM | $-67.12MM | $-96.35MM |
| Non-Operating Income | $1.04MM | $4.50MM | $2.95MM |
| R&D Expense | $38.80MM | $48.03MM | $43.77MM |
| Income(Loss) | $-55.27MM | $-62.62MM | $-93.40MM |
| Taxes | $0.01MM | $0.06MM | $0.04MM |
| Profit(Loss)* | $-55.28MM | $-62.68MM | $-93.44MM |
| Stockholders Equity | $80.75MM | $89.42MM | $11.59MM |
| Assets | $109.97MM | $142.60MM | $66.35MM |
| Operating Cash Flow | $-43.38MM | $-63.30MM | $-70.01MM |
| Capital expenditure | $0.16MM | $1.05MM | $2.34MM |
| Investing Cash Flow | $-65.01MM | $-12.58MM | $80.31MM |
| Financing Cash Flow | $96.26MM | $65.69MM | $8.53MM |
| Earnings Per Share** | $-1.83 | $-1.26 | $-1.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.